Countdown Widget

Join Us

2018/9/17 07:30:00


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships

Presented by Integritas Communications and American Liver Foundation

2nd Annual Massachusetts Opioid Conference 2018

Approximately 25% of all individuals infected with HIV are coinfected with HCV.1 Of critical significance, HIV increases the rate of progression of HCV-related hepatic fibrosis, and HCV is associated with a 3-fold increase in HIV antiretroviral therapy (ART)–induced liver toxicity.Further, these synergistic diseases often occur within adverse socioeconomic conditions that significantly increase the vulnerability and decrease the overall health status of at-risk populations.3 Whereas HIV infection is now effectively manageable, chronic HCV infection is curable. Yet, despite new, highly effective direct-acting antiviral (DAA) treatment regimens for HCV, their broad-scale use and associated therapeutic successes remain stymied by barriers at the patient, clinician, health care system, and jurisdictional levels.4 The BLOCK HIV/HCV initiative will provide community-based infectious disease specialists and other HIV treaters with foundational information and practical resources needed to prepare local stakeholders—both clinical and nonclinical—to collaborate in efforts to eliminate HCV within their communities.

  1. Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis. Accessed January 24, 2018.
  2. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14(6):371-386.
  3. Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco, CA: Jossey-Bass; 2009.
  4. National Viral Hepatitis Roundtable (NVHR). Hepatitis C: The State of Medicaid Access. October 23, 2017. Accessed January 24, 2018.

Program Details

DATE: September 17, 2018
TIME: 7:30 AM – 3:50 PM
LOCATION:St. Anthony Shrine
100 Arch Street
Boston, MA
VIEW MAP: Click Here